Pages that link to "Q73171412"

The following pages link to Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. ApoEurope group (Q73171412):

Displaying 30 items.

• The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease (Q26853347) (← links)
• Effects of Lead and Mercury on the Blood Proteome of Children (Q28383202) (← links)
• Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift (Q28582464) (← links)
• Early Noninvasive Diagnosis of Neurodegenerative Diseases (Q30393556) (← links)
• Relationship between low levels of high-density lipoprotein cholesterol and dementia in the elderly. The InChianti study (Q33790425) (← links)
• Blood-based biomarkers of Alzheimer's disease: challenging but feasible (Q33824444) (← links)
• Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals (Q34305083) (← links)
• Plasma based markers of [11C] PiB-PET brain amyloid burden (Q34427001) (← links)
• Plasma proteins predict conversion to dementia from prodromal disease (Q34556953) (← links)
• Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid (Q34636479) (← links)
• Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort (Q35071184) (← links)
• Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals (Q35076119) (← links)
• Meta-analysis of peripheral blood apolipoprotein E levels in Alzheimer's disease (Q35099780) (← links)
• Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease (Q35114490) (← links)
• Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort (Q35342893) (← links)
• An apolipoprotein E4 fragment affects matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1 and cytokine levels in brain cell lines (Q35981432) (← links)
• Biomarkers of Alzheimer disease in plasma (Q36045288) (← links)
• Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men. (Q36349870) (← links)
• Plasma proteomics for the identification of Alzheimer disease (Q36767124) (← links)
• Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype (Q36888445) (← links)
• Parental history of Alzheimer disease associated with lower plasma apolipoprotein E levels (Q37324697) (← links)
• Both targeted mass spectrometry and flow sorting analysis methods detected the decreased serum apolipoprotein E level in Alzheimer's disease patients (Q37563867) (← links)
• Combination of serum markers related to several mechanisms in Alzheimer's disease (Q44555806) (← links)
• CYP46 T/C polymorphism is not associated with Alzheimer's dementia in a population from Hungary. (Q46782459) (← links)
• The microRNA-1908 up-regulation in the peripheral blood cells impairs amyloid clearance by targeting ApoE. (Q52595828) (← links)
• Myeloperoxidase G-463A polymorphism and Alzheimer's disease in the ApoEurope study. (Q53256331) (← links)
• The Role of ApoE Polymorphism in the Relationship between Serum Steroid Hormone Levels and Cognition in Older Chinese Adults: A Cross-Sectional Study. (Q55002052) (← links)
• Molecular Mechanisms in Alzheimer's Disease. (Q55506979) (← links)
• 'Evolutionary medicine' perspectives on Alzheimer's Disease: Review and new directions (Q57174334) (← links)
• Cortisol, HDL-c, VLDL-c, and APOE Polymorphisms as Laboratorial Parameters Associated to Cognitive Impairment No Dementia (CIND) and Dementia (Q85961131) (← links)